1. [CASE 1 -- QUESTION 1] The tilt-table test result -- progressive bradycardia AND hypotension -- characterizes the autonomic response. Which of the following most accurately classifies this response type, explains the receptor-level mechanism of the simultaneous bradycardia and hypotension, and distinguishes it from the two other major tilt-table response patterns?

• A) The simultaneous bradycardia and hypotension is a Type 1 Mixed vasovagal response (VASIS classification) -- the cardioinhibitory and vasodepressor components both contribute; the mechanism involves two simultaneous autonomic events: (1) Sudden withdrawal of sympathetic alpha-1 tone to the peripheral vasculature (vasodepressor component) -- producing vasodilation and hypotension; and (2) Sudden increase in vagal M2 tone to the SA node (cardioinhibitory component) -- producing bradycardia; together these overcome compensatory mechanisms and produce syncope; the other two major patterns are: Type 2A Cardioinhibitory without asystole (bradycardia predominates, HR below 40 bpm for more than 10 seconds, BP drops secondary to low cardiac output, but no asystole); Type 2B Cardioinhibitory with asystole (asystole greater than 3 seconds, typically following after BP has already fallen); Type 3 Vasodepressor (HR does not fall more than 10% from peak at time of syncope, hypotension is from vasodilation alone without significant vagal cardioinhibition) -- all per the VASIS (Vasovagal Syncope International Study) classification.
• B) The simultaneous bradycardia and hypotension represents a sympathetic surge response misclassified as vasovagal -- the tilt-table result actually shows the fight-or-flight response with alpha-1 vasoconstriction producing the initial BP rise (not seen in the data) followed by beta-2 vasodilation causing hypotension; the bradycardia is a Bezold-Jarisch reflex from the vigorous cardiac sympathetic stimulation activating ventricular C-fibers; treatment is beta-blockade to prevent the initial sympathetic surge.
• C) The response pattern with combined bradycardia and hypotension is always pathological and indicates complete autonomic failure rather than vasovagal syncope -- in true vasovagal syncope, either bradycardia OR hypotension occurs, never both simultaneously; simultaneous bradycardia and hypotension during tilt indicates primary autonomic neuropathy with failure of both baroreflex arcs (adrenergic and cholinergic); this patient requires evaluation for Parkinson disease, multiple system atrophy, and hereditary sensory and autonomic neuropathies.
• D) The mixed vasovagal response during tilt reflects a reflex arc triggered by ventricular mechanoreceptors detecting underfilling of the ventricle during upright posture -- during prolonged standing or head-up tilt, venous pooling reduces ventricular preload; the relatively empty but vigorously contracting ventricle activates mechanosensitive C-fibers in the inferoposterior left ventricular wall (the Bezold-Jarisch reflex afferent); these C-fibers signal via vagal afferents to the NTS, which simultaneously activates vagal efferents (producing bradycardia via M2 activation at SA node) and inhibits RVLM sympathetic outflow (producing vasodilation from withdrawal of alpha-1 vasoconstrictor tone); the response is therefore a reflex-mediated simultaneous vagal activation and sympathetic withdrawal -- the mechanism of classic vasovagal syncope; it differs from: (1) orthostatic hypotension (gradual BP fall within 3 minutes of standing from fixed autonomic failure -- no reflex bradycardia, no prodrome, no recovery with supine positioning; caused by sympathetic denervation); (2) POTS (postural orthostatic tachycardia syndrome -- HR rise greater than 30 bpm without syncope from compensatory sympathetic activation in the absence of adequate venous return).

2. [CASE 1 -- QUESTION 2] The neurologist discusses pharmacological treatment options for the vasovagal syncope. Given the military operational context (deploying in 4 months, must be able to function reliably in combat), which of the following most accurately explains the receptor mechanisms of three pharmacological options and their respective suitability for this patient?

• A) Three pharmacological options with receptor mechanisms: (1) Fludrocortisone (mineralocorticoid receptor agonist -- increasing renal sodium and water retention, expanding intravascular volume, and sensitizing peripheral alpha-1 adrenergic receptors to catecholamines) -- increases preload and ventricular filling, reducing the trigger stimulus for the Bezold-Jarisch reflex; has no acute CNS effects impairing combat performance; suitable for this patient; (2) Midodrine (selective alpha-1A adrenergic agonist -- increasing peripheral vascular resistance and reducing venous pooling in the lower extremities, raising standing BP and maintaining ventricular filling) -- prevents the venous pooling-triggered reflex; must be taken 3 times daily and avoided before lying supine (supine hypertension); no CNS effects; suitable for operational use but dosing logistics require attention; (3) Beta-blockers (metoprolol, atenolol -- proposed mechanism: reducing the vigorous ventricular contractions that activate Bezold-Jarisch C-fiber afferents by reducing beta-1-mediated inotropy; reducing the sympathetic surge preceding the syncopal reflex) -- randomized controlled trials (POST I, POST II, ISSUE-3) have shown that oral beta-blockers are not superior to placebo for vasovagal syncope in most patients under 42 years old; the proposed mechanism is not well-supported by clinical evidence; beta-blockade in an active-duty combat medic may impair the appropriate physiological stress response (exercise heart rate, fight-or-flight response) and reduce combat performance -- not appropriate for this patient.
• B) The only pharmacological treatment with proven efficacy for vasovagal syncope is atropine -- atropine blocks the M2 vagal cardioinhibitory component (preventing bradycardia), and this has been validated in multiple large randomized trials as the standard of care; atropine 0.6 mg orally twice daily is the recommended regimen; in a combat medic, atropine is ideal because it has the additional benefit of providing prophylaxis against potential organophosphate nerve agent exposure in the field; atropine is available in military autoinjectors and is already part of the standard military pharmacological kit.
• C) Ivabradine (selective HCN channel blocker reducing the If funny current, selectively slowing SA node automaticity without affecting contractility, AV conduction, or peripheral vasomotion) is the treatment of choice for this patient -- by reducing the resting HR from 70 to 55 bpm, ivabradine blunts the Bezold-Jarisch trigger (the vigorous ventricular contraction of an underfilled heart) by reducing heart rate without affecting inotropy or vascular tone; ivabradine has no effect on exercise capacity (since exercise-induced heart rate increase via adrenergic receptors is preserved); the military can approve ivabradine for combat duty because it does not impair the sympathetic stress response; ivabradine has been proven superior to beta-blockers in multiple head-to-head vasovagal syncope trials.
• D) Pyridostigmine (reversible AChE inhibitor) is the most mechanistically rational treatment for vasovagal syncope -- by preventing ACh breakdown, pyridostigmine increases resting vagal tone at the SA node, producing a slower resting heart rate; this paradoxically prevents vasovagal syncope by pre-loading the parasympathetic system, reducing the relative magnitude of the vagal surge during the Bezold-Jarisch reflex; randomized controlled trials have confirmed pyridostigmine as first-line pharmacological therapy for vasovagal syncope with a 78% reduction in syncope frequency versus placebo.

3. [CASE 1 -- QUESTION 3] The neurologist recommends a trial of midodrine 5 mg three times daily. Six weeks later the patient reports no syncopal episodes and only one presyncopal episode during a video-heavy lecture, aborted by sitting down. However, he notes that his scalp itches, he has goosebumps on his forearms and upper back in warm conditions, and he has difficulty voiding if he takes his evening dose too close to bedtime. Which of the following most accurately explains the receptor mechanism of each adverse effect and confirms they are predictable from midodrine pharmacology?

• A) The scalp pruritus is from midodrine crossing the blood-brain barrier and activating central histamine H1 receptors -- midodrine is a small lipophilic molecule with significant CNS penetration; central H1 activation produces pruritus, sedation, and urinary hesitancy through a centrally mediated pathway; midodrine should be discontinued and replaced with fludrocortisone which has better CNS tolerability; the piloerection and voiding difficulty are unrelated to midodrine and represent a separate allergic reaction.
• B) All three adverse effects are predictable alpha-1A receptor-mediated effects of midodrine (as desglymidodrine) at non-target tissues: (1) Scalp pruritus and piloerection (goosebumps): desglymidodrine activates alpha-1A receptors on the arrector pili smooth muscles throughout the skin -- alpha-1A activation contracts arrector pili muscles, producing piloerection (goosebumps); cutaneous alpha-1A activation may also cause pilomotor nerve activation that produces pruritus, particularly prominent in the scalp where pilomotor density is high; (2) Supine hypertension: desglymidodrine activates alpha-1A receptors throughout the peripheral vasculature when the patient is supine, increasing vascular resistance without the compensatory gravitational venodilation present in the upright position -- producing potentially significant supine hypertension; patients should not lie flat within 4 hours of a dose; (3) Urinary hesitancy: alpha-1A receptors are expressed in the prostate, bladder neck, and internal urethral sphincter smooth muscle -- alpha-1A activation increases internal sphincter tone, producing urinary hesitancy or retention; this is the same mechanism by which alpha-1A agonism causes BPH-like symptoms even in young men; taking the evening dose close to bedtime produces urinary hesitancy that interferes with voiding before sleep.
• C) The scalp pruritus and piloerection are central nervous system side effects confirming that midodrine crosses the blood-brain barrier in amounts sufficient to activate central alpha-1 receptors in the hypothalamus -- these hypothalamic alpha-1 receptors mediate thermoregulatory responses including piloerection (a heat-conservation response) and pruritus (a hypothalamic-mediated itch response); the urinary difficulty confirms additional muscarinic M1 receptor blockade in the bladder -- midodrine has significant anticholinergic off-target activity that produces urinary retention through a different mechanism than its primary alpha-1A activity.
• D) The adverse effects confirm midodrine is too potent for this patient -- all three effects are dose-limiting toxicities from alpha-1A receptor saturation; the scalp pruritus results from mast cell alpha-1A receptor activation causing local histamine release; piloerection results from sympathetic alpha-1A nerve terminal activation causing NE release that then activates arrector pili; urinary hesitancy results from alpha-1A activation of both detrusor and sphincter simultaneously producing a dyscoordinated voiding reflex; midodrine should be halved to 2.5 mg three times daily to reduce receptor saturation.

4. [CASE 1 -- QUESTION 4] Three months after starting midodrine, the patient deploys successfully. However, during a prolonged mission requiring 18 hours of sustained physical activity in extreme heat (ambient temperature 46 degrees Celsius), he develops progressive confusion, HR 148 bpm, rectal temperature 41.8 degrees Celsius, and cessation of sweating despite the extreme heat. His medic partner recognizes heat stroke. The field physician considers the pharmacological interactions that may have contributed to this presentation. Which of the following most accurately identifies any pharmacological contribution from midodrine to the heat stroke and guides field management?

• A) Midodrine (desglymidodrine, alpha-1A agonist) has contributed to the heat stroke through two mechanisms: (1) alpha-1A-mediated cutaneous vasoconstriction reducing skin blood flow and impairing convective heat dissipation -- the normal thermoregulatory response to heat is cutaneous vasodilation (alpha-1 withdrawal plus active vasodilatory mechanisms) to increase skin blood flow and enhance radiant and convective heat loss; midodrine-maintained alpha-1A tone in cutaneous vasculature opposes this heat-dissipating vasodilation, reducing one of the three major heat loss mechanisms (radiation, convection, and evaporation); (2) No direct effect on sweating -- midodrine does not block muscarinic receptors and does not affect eccrine sweat gland function; the cessation of sweating in heat stroke reflects the breakdown of the thermoregulatory system from hyperthermia itself (central thermoregulatory failure at extreme core temperatures), not from any pharmacological anhidrosis; field management: immediate active cooling (ice water immersion is most effective -- reduces temperature by 0.2 degrees Celsius per minute; evaporative cooling with fans if immersion unavailable); hold midodrine until the patient is hemodynamically stable and ambient conditions are controlled; IV fluid resuscitation with monitoring for rhabdomyolysis (urine myoglobin, CK); benzodiazepines for shivering or seizures; evacuate.
• B) Midodrine has no pharmacological contribution to the heat stroke -- the heat stroke is purely from environmental heat load and physical exertion; midodrine does not affect any thermoregulatory mechanism; the cessation of sweating is entirely from central thermoregulatory failure; field management is immediate active cooling without any medication changes.
• C) Midodrine caused the heat stroke through direct hypothalamic alpha-1A receptor activation -- midodrine crosses the blood-brain barrier in sufficient quantities to activate hypothalamic alpha-1A receptors, which when activated raise the thermoregulatory set point by 2-3 degrees Celsius; this elevated set point allows core temperature to rise to 41.8 degrees Celsius before the hypothalamus initiates sweating; the pharmacological fix is to give the patient an alpha-1 blocker (phentolamine) to restore the normal thermoregulatory set point.
• D) Midodrine produced the cessation of sweating through alpha-1A receptor activation on eccrine sweat glands -- eccrine sweat glands express alpha-1A adrenergic receptors that when activated produce vasoconstriction of the gland vasculature, starving the secretory coil of blood flow and preventing sweat production even with intact sympathetic cholinergic drive to the gland; the cessation of sweating is therefore a pharmacological anhidrosis from midodrine rather than central thermoregulatory failure; treatment is to administer a muscarinic agonist (pilocarpine) to directly stimulate sweat secretion and bypass the alpha-1A vascular blockade of the gland vasculature.

5. [CASE 2 -- QUESTION 1] The ECG during tachycardia shows a narrow-complex tachycardia with very short RP interval (P wave just after QRS), terminating abruptly. The autonomic pharmacologist is asked to explain the relationship between the suppressed TSH, the tachycardia mechanism, and her orthostatic hypotension. Which of the following most accurately integrates these findings?

• A) The narrow-complex tachycardia with short RP interval and abrupt termination is diagnostic of atrioventricular nodal reentrant tachycardia (AVNRT) -- the most common form of paroxysmal supraventricular tachycardia; in typical AVNRT, the reentrant circuit uses the slow pathway anterogradely and the fast pathway retrogradely, placing the retrograde P wave just after the QRS (RP less than 70 ms); the suppressed TSH indicates exogenous levothyroxine excess (iatrogenic thyrotoxicosis) -- thyroid hormone excess upregulates beta-1 adrenergic receptor expression in the heart (by increasing beta-1 receptor mRNA transcription) and sensitizes the SA and AV nodes to catecholamines; additionally, thyroid hormone directly increases myocardial calcium handling (increasing SERCA2a expression and If current) and shortens action potential duration -- creating a proarrhythmic substrate in the AV node that facilitates AVNRT; the orthostatic hypotension results from thyrotoxicosis-induced reduction in systemic vascular resistance (thyroid hormone directly relaxes vascular smooth muscle via non-genomic mechanisms and reduces alpha-1 receptor expression) combined with possible mild volume depletion from thyrotoxicosis-induced sweating and tachycardia-mediated reduced cardiac filling time; levothyroxine dose reduction is the primary treatment to address the underlying proarrhythmic state.
• B) The narrow QRS tachycardia with short RP interval terminating abruptly is ventricular tachycardia from the right ventricular outflow tract -- thyrotoxicosis from levothyroxine overdose causes direct thyroid hormone-mediated myocarditis of the RVOT; TSH suppression confirms thyrotoxicosis but is not causally related to the arrhythmia; the orthostatic hypotension is from amlodipine-mediated peripheral vasodilation; treatment is flecainide for the RVOT-VT and dose reduction of amlodipine.
• C) The suppressed TSH confirms iatrogenic thyrotoxicosis from levothyroxine dose excess -- thyroid hormone (T3, the active form derived from levothyroxine T4 by peripheral deiodinase) upregulates beta-1 adrenergic receptor density and sensitivity in cardiac conduction tissue, shortens the AV nodal refractory period, increases the slope of spontaneous diastolic depolarization (If current upregulation), and reduces systemic vascular resistance; these changes create a proarrhythmic substrate facilitating AVNRT (a reentrant SVT using the dual AV nodal pathway) and contribute to the orthostatic hypotension from reduced SVR; the narrow-complex tachycardia at 158 bpm with retrograde P wave (RP less than 70 ms) and abrupt termination is highly characteristic of AVNRT; acute treatment: vagal maneuvers (Valsalva -- increases intrathoracic pressure, reducing venous return and transiently increasing aortic pressure, triggering baroreceptor-mediated vagal surge that slows AV nodal conduction and may terminate the reentrant circuit); if unsuccessful, adenosine 6 mg IV rapid push (activates adenosine A1 receptors on AV nodal cells via Gi/GIRK -- producing transient AV nodal block, interrupting the reentrant circuit); long-term: reduce levothyroxine dose to achieve TSH 0.5-2.5 mIU/L; if AVNRT persists after euthyroid state is restored, electrophysiology study and slow pathway ablation.
• D) The orthostatic hypotension, tachycardia, and palpitations all result from amlodipine toxicity -- amlodipine has a very long half-life (30-50 hours) and accumulates in elderly patients with reduced hepatic clearance; at toxic plasma levels, amlodipine produces severe peripheral vasodilation (orthostatic hypotension), reflex tachycardia (baroreceptor-driven beta-1 activation -- which can degenerate into AVNRT through accelerated AV nodal conduction), and direct L-type calcium channel blockade contributing to vascular hyporeactivity; the suppressed TSH is an unrelated incidental finding of no significance.

6. [CASE 2 -- QUESTION 2] The cardiologist administers adenosine 6 mg IV rapid push during a captured episode of tachycardia in the clinic. The arrhythmia terminates within 12 seconds. The patient asks why a drug to fix her heart made her feel like she was dying briefly. Which of the following most accurately explains the complete pharmacology of adenosine including its receptor mechanism, the basis for its extremely short duration of action, and the mechanism of its side effects?

• A) Adenosine is a direct muscarinic M2 agonist at the AV node -- it produces the identical electrophysiological effects as acetylcholine (hyperpolarization via IKACh/GIRK activation and reduced cAMP) through direct M2 receptor binding; its extremely short duration of action is explained by rapid hydrolysis by plasma acetylcholinesterase (the same enzyme hydrolyzing ACh at autonomic synapses); the side effects (chest tightness, flushing, dyspnea) result from M2 receptor activation in bronchial smooth muscle; aminophylline and caffeine (methylxanthines) are adenosine antidotes because they competitively block M2 receptors, reversing adenosine effects.
• B) Adenosine activates Gi-coupled adenosine A1 receptors on SA and AV nodal cells: A1 receptor activation releases Gi betagamma subunits which directly activate IKACh (GIRK1/GIRK4) channels producing hyperpolarization and reducing the slope of spontaneous diastolic depolarization; additionally, Galphai inhibits adenylyl cyclase reducing cAMP and suppressing If current; these two mechanisms together slow SA node automaticity and markedly prolong AV nodal refractory period -- temporarily blocking AV conduction and interrupting the AVNRT circuit; adenosine also acts at A2A receptors on coronary and systemic vascular smooth muscle (Gs-mediated vasodilation), bronchial smooth muscle (A2B and A3, causing bronchoconstriction in susceptible individuals), and sensory C-fibers (producing chest pain and dyspnea perception); extreme brevity of action: adenosine is taken up within 10 seconds by erythrocytes (via equilibrative nucleoside transporter ENT1) and vascular endothelium, and rapidly deaminated to inosine by adenosine deaminase; plasma half-life is less than 10 seconds; dipyridamole (inhibits ENT1 uptake) and aminophylline/caffeine (competitive A1/A2 receptor antagonists) are the pharmacological antagonists; side effects: flushing (A2A vasodilation), chest pressure (C-fiber A1 activation mimicking cardiac ischemia pain), dyspnea (diaphragmatic C-fiber activation, bronchial smooth muscle A2B/A3 bronchoconstriction), and transient sinus arrest or AV block.
• C) Adenosine is an endogenous purine nucleoside that activates A1 receptors (Gi-coupled, GIRK activation) on AV nodal cells to terminate SVT; its plasma half-life of less than 10 seconds results from enzymatic deamination by adenosine deaminase; methylxanthines (caffeine, theophylline) are competitive A1 receptor antagonists that reduce adenosine efficacy -- patients who drink large amounts of coffee may require higher adenosine doses for SVT termination; patients on dipyridamole (which blocks adenosine uptake into red blood cells via ENT1) have dramatically prolonged adenosine effects and require dose reduction to 3 mg.
• D) Adenosine terminates SVT by activating cardiac muscarinic M4 receptors -- M4 receptors are expressed exclusively in the AV node (not at the SA node) and when activated produce a profound GIRK-mediated hyperpolarization that selectively blocks AV nodal conduction without affecting SA node automaticity; the M4 selectivity explains why adenosine produces AV block without sinus arrest; atropine (M4 antagonist at the AV node) reverses adenosine-induced AV block; methylxanthines are effective adenosine antidotes because they also have M4 antagonist properties at the AV node in addition to their phosphodiesterase-inhibiting effects.

7. [CASE 2 -- QUESTION 3] After the levothyroxine dose is reduced and TSH normalizes to 1.2 mIU/L three months later, she continues to have occasional AVNRT episodes (2-3 per month, self-terminating within 5 minutes). The cardiologist offers beta-blocker therapy for chronic suppression. She is concerned about her exercise tolerance and insists on continuing her 5-mile daily walks. Which of the following most accurately explains the receptor-level tradeoff between beta-blockade for AVNRT suppression and exercise performance, and identifies the beta-blocker property most relevant to minimizing exercise limitation?

• A) Beta-blockers are absolutely contraindicated for chronic AVNRT suppression in active patients -- beta-blockade reduces the maximum heart rate achievable during exercise by blocking beta-1 adrenergic receptors at the SA node, preventing the normal catecholamine-driven chronotropic response; this reduces maximum cardiac output by 20-30%, severely limiting aerobic exercise capacity; the appropriate alternative for this patient is flecainide (sodium channel blocker) which provides excellent AVNRT suppression without any effect on exercise heart rate, as flecainide does not act on adrenergic receptors.
• B) Beta-1 selective blockers (metoprolol, bisoprolol, atenolol) suppress AVNRT recurrence by reducing sympathetic adrenergic facilitation of AV nodal conduction -- catecholamine-mediated beta-1 receptor activation in the AV node increases cAMP, enhancing L-type calcium channel conductance and accelerating conduction through the dual AV nodal pathway, facilitating reentry; beta-1 blockade reduces this adrenergic facilitation, slowing AV nodal conduction and reducing the frequency of AVNRT initiation; exercise limitation: beta-1 blockade reduces maximum heart rate during exercise (blunted chronotropic response to exercise catecholamines) by approximately 20-30 bpm at peak exercise, reducing maximum cardiac output and VO2 max (maximum oxygen consumption -- the standard measure of aerobic exercise capacity) by approximately 10-15% in otherwise healthy individuals; for an active exerciser this is clinically meaningful but generally tolerable; beta-1 selective agents are preferred over non-selective agents (propranolol) because they do not block beta-2-mediated skeletal muscle vasodilation and glycogenolysis during exercise, which are important for sustained aerobic performance; beta-1 selectivity is the key property; the patient should be counseled that perceived exertion will be higher at a given workload and maximum achievable heart rate will be lower, but walking at her current pace may be well tolerated.
• C) Non-selective beta-blockers (propranolol) are preferred over cardioselective agents for AVNRT suppression in active patients because propranolol also blocks beta-2 receptors in the AV nodal bypass tract -- the accessory pathway in AVNRT expresses beta-2 receptors (unlike the main AV node which expresses only beta-1), and blocking beta-2 provides additional accessory pathway suppression beyond what cardioselective agents achieve; the beta-2 blockade-related exercise limitation is acceptable and actually beneficial because it prevents excessive exercise-induced tachycardia that could trigger AVNRT in susceptible patients.
• D) The relevant beta-blocker property for minimizing exercise limitation in this patient is intrinsic sympathomimetic activity (ISA) -- beta-blockers with ISA (pindolol, acebutolol) partially activate beta-1 receptors while blocking the full catecholamine response; at rest, ISA maintains some beta-1 activity preventing excessive bradycardia and minimizing fatigue; during exercise, when catecholamine levels rise substantially above the partial agonist activity threshold, the drug becomes primarily antagonist (blocking the catecholamine-driven HR increase), providing AVNRT suppression; for this active patient, a beta-blocker with ISA provides better exercise tolerance than a pure antagonist (metoprolol) because the ISA component maintains cardiac output during moderate-intensity activity; pindolol is the preferred choice.

8. [CASE 2 -- QUESTION 4] She is started on metoprolol succinate 25 mg daily. Six months later, she presents to her internist with worsening fatigue and cold intolerance. Repeat TSH is now 8.4 mIU/L (elevated). Her free T4 is low-normal. The internist notes that her levothyroxine dose was already reduced from 125 mcg to 100 mcg three months ago (when TSH normalized) and then further reduced to 88 mcg six weeks ago due to a continued TSH of 0.6 mIU/L. The pharmacology consultant is asked about a possible pharmacokinetic drug interaction between metoprolol and levothyroxine. Which of the following most accurately identifies the interaction and guides management?

• A) Metoprolol directly inhibits thyroid hormone synthesis by blocking the beta-1 adrenergic receptors on thyroid follicular cells that mediate TSH-stimulated thyroid hormone production -- beta-1 blockade reduces cAMP in follicular cells, impairing the TSH-mediated thyroid peroxidase activation required for iodination and coupling of thyroid hormones; this explains why the TSH has risen despite levothyroxine being provided exogenously -- the exogenous T4 cannot compensate for the metoprolol-mediated impairment of its own biological activity at the follicular receptor level.
• B) Metoprolol inhibits peripheral conversion of T4 to the active T3 by blocking the type 1 deiodinase enzyme (D1) in the liver and kidney -- D1 is a beta-1-stimulated enzyme that converts the prohormone T4 to the active hormone T3; beta-1 blockade reduces D1 activity, increasing the T4:T3 ratio and reducing the biological activity of the circulating thyroid hormone despite normal or elevated T4 levels; this produces a functional hypothyroid state with elevated TSH despite adequate T4 supplementation; the correct management is to increase levothyroxine dose to compensate for the reduced peripheral T4-to-T3 conversion, not to stop metoprolol.
• C) Beta-blockers including metoprolol reduce peripheral conversion of T4 to T3 by inhibiting type 1 deiodinase (D1) -- this pharmacological effect is actually therapeutically exploited in thyrotoxicosis (propranolol is given to thyrotoxic patients specifically to reduce T4-to-T3 conversion, reducing the amount of biologically active T3); in this patient who requires adequate thyroid hormone replacement, the metoprolol-mediated reduction in T4-to-T3 conversion has reduced T3 levels and increased TSH despite adequate T4 supplementation; additionally, metoprolol is metabolized by CYP2D6 and thyroid status affects CYP2D6 activity (hypothyroidism reduces CYP2D6 activity, causing metoprolol accumulation which further suppresses deiodinase); the management is to increase levothyroxine dose (targeting TSH 0.5-2.5 mIU/L) rather than stopping the beta-blocker; monitoring the TSH response after levothyroxine adjustment will guide the final dose.
• D) There is no pharmacokinetic or pharmacodynamic interaction between metoprolol and levothyroxine -- the TSH elevation to 8.4 mIU/L is simply from the sequential levothyroxine dose reductions (from 125 to 100 to 88 mcg over 3 months) being excessive; the half-life of levothyroxine is approximately 7 days, meaning that each dose change takes 4-6 weeks to reach a new steady-state TSH; the two consecutive reductions in a short time period compounded to produce excessive hypothyroidism without adequate time between adjustments to assess the TSH response at each new dose; the management is to return the levothyroxine dose to 100 mcg (the dose at which TSH was normalized) and reassess TSH in 6 weeks.